IO Biotech has concluded subject enrolment in the Phase III IOB-013/KN-D18 clinical trial for IO102-IO103 combination therapy to treat advanced melanoma.
Sponsored by IO Biotech, the randomised, open-label pivotal trial will analyse IO102-IO103 along with pembrolizumab compared to pembrolizumab alone for priorly untreated, unresectable or metastatic (advanced) melanoma.
The trial has so far enrolled a total of 380 subjects at study sites across Australia, the US, Europe, Israel, South Africa and Turkey.
The company will carry out a per-protocol interim assessment of the study mid-next year.
Progression-free survival is the trial’s primary endpoint with analysis slated to be carried out in the second half of 2025.
An investigational cancer vaccine, IO102-IO103 acts on the immunosuppressive mechanisms.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
MSD is providing its anti-PD-1 therapy pembrolizumab required for the trial.
IO Biotech president and CEO Mai-Britt Zocca said: “The Phase I/II data of IO102-IO103 in combination with a PD-1 inhibitor in patients with first-line advanced melanoma demonstrated approximately double the effect than would have been expected with PD-1 inhibitor monotherapy in this patient population – with 80% of patients achieving a response, 50% of patients achieving a complete response, and no additional systemic toxicity than that typically seen with a PD-1 inhibitor alone.
“Completion of enrolment in this pivotal Phase III trial marks a significant milestone for our company and is a testament to the enthusiasm for this study among our investigators and the patient community.”